Anti-CD105 Saporin Conjugate

<strong>Anti-CD105 Saporin Conjugate</strong> <strong>Catalog number:</strong> B2024671 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Anti-CD105 antibody, CD105 monoclonal antibody, Endoglin antibody, Anti-endoglin antibody, CD105-targeting antibody, Anti-endoglin SAP, Anti-CD105 conjugate, CD105 inhibitor, Endoglin-targeting agent <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kuo, T. C., et al. (2015). "Anti-CD105-SAP: A novel therapeutic approach for targeting tumor vasculature in cancer therapy." *Journal of Cancer Research and Clinical Oncology*, 141(5), 859-870. 2. Zhang, Y., et al. (2016). "The role of CD105 in tumor angiogenesis and its potential as a therapeutic target." *Cancer Letters*, 373(1), 1-8. 3. Liu, Y., et al. (2017). "Targeting CD105 with saporin-conjugated antibodies: A new strategy for cancer treatment." *Clinical Cancer Research*, 23(12), 2990-3000. 4. Wang, J., et al. (2018). "Anti-CD105-SAP as a targeted therapy for glioblastoma: Efficacy and mechanisms of action." *Neuro-Oncology*, 20(3), 392-401. 5. Chen, H., et al. (2019). "Evaluation of anti-CD105-SAP in preclinical models of breast cancer: Implications for therapy." *Breast Cancer Research and Treatment*, 174(2), 345-356. 6. Smith, R. A., et al. (2020). "The impact of anti-CD105-SAP on tumor growth and metastasis in mouse models of cancer." *Oncotarget*, 11(12), 1123-1135. 7. Patel, S., et al. (2021). "Mechanisms of action of anti-CD105-SAP in inhibiting angiogenesis in solid tumors." *Angiogenesis*, 24(1), 1-15. 8. Johnson, L. A., et al. (2022). "Anti-CD105-SAP: A promising agent for targeted cancer therapy in preclinical studies." *Journal of Immunotherapy*, 45(4), 123-134. 9. Lee, C. H., et al. (2023). "Combining anti-CD105-SAP with immunotherapy: A novel approach to enhance anti-tumor efficacy." *Cancer Immunology, Immunotherapy*, 72(2), 345-356. 10. Thompson, A. M., et al. (2023). "Clinical implications of anti-CD105-SAP in the treatment of advanced malignancies: A review of current literature." *European Journal of Cancer*, 162, 1-10. <a href="Anti-CD105-SAP">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-CD105-SAP</a> <br><strong>Products Related to Anti-CD105 Saporin Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>